Comparison
BPC-157 vs Nicotinamide Riboside
Side-by-side of BPC-157 and Nicotinamide Riboside. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
BPC-157
BPC-157 peptide profile: pentadecapeptide body protection compound 157. Preclinical data on tendon, gut healing, recovery. No human RCTs as of 2026.
Nicotinamide Riboside
Nicotinamide riboside (NR) is the most-studied NAD+ precursor in humans. Sold as Niagen by Chromadex; raises plasma NAD+ 30-60% at 250-1,000 mg/day.
Effects at a glance
BPC-157
- •Preclinical models show accelerated tendon-to-bone and ligament healing after surgical or chemical injury
- •Rodent studies report mucosal protection and faster recovery from NSAID-induced and colitis-induced gut damage
- •Anecdotal human protocols use 250 to 500 mcg twice daily subcutaneously near the injury site
- •No completed phase II or III human RCTs as of 2026, so efficacy and long-term safety remain unestablished
- •Banned by WADA since 2022 under the S0 non-approved substances category for competitive athletes
- •Theoretical angiogenic concern means avoidance is prudent in active malignancy until human data exists
Nicotinamide Riboside
- •Most-studied NAD+ precursor in human trials; the original Niagen formulation by Chromadex
- •Plasma NAD+ rises 30-60% at 250-1,000 mg/day across multiple human PK trials
- •Martens 2018 reported reduced BP and arterial stiffness at 500 mg/day for 6 weeks
- •Dollerup 2018 found no insulin sensitivity change despite plasma NAD+ rise
- •Tissue NAD+ rise inconsistent; hard clinical endpoints not yet measured
- •Larger human safety database than NMN; comparable mechanistic effects
Side-by-side
| Attribute | BPC-157 | Nicotinamide Riboside |
|---|---|---|
| Category | peptide | supplement |
| Also known as | Body Protection Compound-157, Pentadecapeptide BPC-157 | NR, Niagen, nicotinamide riboside chloride |
| Half-life (hr) ↗ | 4 | 8 |
| Typical dose (mg) ↗ | 0.25 | 500 |
| Dosing frequency | daily (anecdotal protocols) | daily, typically morning |
| Routes | subcutaneous, intramuscular, oral | oral |
| Onset (hr) | - | 1 |
| Peak (hr) | - | 4 |
| Molecular weight | - | 255.25 |
| Molecular formula | C62H98N16O22 | C11H15N2O5 |
| Mechanism | Proposed upregulation of VEGFR2 and nitric oxide pathways, modulation of growth-hormone receptor expression, and stabilization of gut-brain axis signaling. Mechanism remains largely preclinical. | NAD+ precursor via salvage pathway. Phosphorylated to NMN by nicotinamide riboside kinase (NRK), then converted to NAD+. Substrate for sirtuins, PARPs, and CD38. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA (2022) | OTC dietary supplement |
| WADA status | banned | allowed |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | OTC supplement |
| Pregnancy | Insufficient data | Insufficient data at supplement doses |
| CAS | 137525-51-0 | 1341-23-7 |
| PubChem CID | 9941957 | 439924 |
| Wikidata | Q4835418 | Q3343054 |
Safety profile
BPC-157
Common side effects
- injection-site irritation
- nausea
- headache (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established safety profile in humans
Nicotinamide Riboside
Common side effects
- mild GI upset (rare)
- headache (rare)
Contraindications
- pregnancy / lactation (insufficient data)
- active cancer (theoretical, no contraindicating data)
Interactions
- pterostilbene: complementary sirtuin pathway (Basis combination)(minor)
- TMG (trimethylglycine): methylation support during high NAD+ precursor dosing(minor)
Which Should You Take?
Nicotinamide Riboside comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. BPC-157 is the right call when one of the conditionals below applies.
- → If your priority is post-training recovery, pick BPC-157.
- → If your priority is gut barrier and microbiome health, pick BPC-157.
- → If your priority is healthspan extension, pick Nicotinamide Riboside.
- → If your priority is energy and stamina, pick Nicotinamide Riboside.
Edge case: If you want to avoid research-only / gray-market sourcing, Nicotinamide Riboside is the more accessible choice.
Default choice: Nicotinamide Riboside. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for BPC-157 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between BPC-157 and Nicotinamide Riboside?
BPC-157 and Nicotinamide Riboside differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, BPC-157 or Nicotinamide Riboside?
BPC-157 half-life is 4 hours; Nicotinamide Riboside half-life is 8 hours.
Can you stack BPC-157 with Nicotinamide Riboside?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper